The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Pazopanib
Pazopanib · PAZOPANIB HYDROCHLORIDE 200 mg/1 · Tablet, Film Coated · Oral · AvKARE
NDC 42291-0939-12 · 120 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$11,349.33
Reported to Texas DSHS · 2026 annual filing · AvKare
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- ANDA217517
- TE code
- AB
- Approval date
- Oct 19, 2023
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Pazopanib (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Aurobindo Pharma Limited | PAZOPANIB HYDROCHLORIDE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | PAZOPANIB HYDROCHLORIDE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | PAZOPANIB HYDROCHLORIDE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals, Inc. | PAZOPANIB HYDROCHLORIDE 200 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Pazopanib — NDC 42291-0939-12," retrieved September 3, 2026, https://drugdashboards.com/drug/42291093912.
Free to cite with attribution — see how the data is put together.